CommercialCoverageMedium impact
Drug Policy Criteria Change
Arkansas Blue Cross Blue Shield·Infectious Disease, Oncology, Critical Care·Pharmacy
Effective date
Jul 12, 2026
We identified it
Jun 19, 2026
Summary
Several antifungal and antibiotic medications have updated coverage criteria effective July 12, 2026. Key changes include adding newly FDA-approved voriconazole injection to formularies, updating quantity limits for Abelcet and AmBisome based on new reference data, and removing discontinued brand products like Invanz and Dapzura RT from coverage lists.
Action Required
By July 12, 2026: Billing team must update drug formulary lists to include newly approved voriconazole injection for prior authorization requirements. Remove brand Invanz, Dapzura RT, and levofloxacin 750mg/30mL vial from billable drug lists as these products are no longer available. Update quantity limit guidelines for Abelcet and AmBisome in billing system to reflect new anthropometric reference standards.